ActRIIA Enzyme Activity Inhibitor Screening Kit Isotype control B- and T-lymphocyte-associated protein

B- and T-lymphocyte-associated protein

which presents advantages for drug development targeting this receptor

NDRG1 is a potent

Effects of interleukin-2 in immunostimulation and immunosuppression

Tissue homogenate:The tissues were washed with pre-cooled PBS (0

ActRIIA Enzyme Activity Inhibitor Screening Kit Isotype control B- and T-lymphocyte-associated proteinProduct Specification Species Human Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibition of the ACTRII signaling pathway has been shown to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving